SCHEMBL276376

SCHEMBL276376

C=C(N=Cc1cc(F)ccc1OC1CCOCC1)O[Si](C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.39
KAT2B Q92831 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
NTRK1 P04629 2/20 0.38
PDE4D Q08499 7/20 0.37
PDE4A P27815 5/20 0.37
PDE4B Q07343 5/20 0.37
PDE4C Q08493 5/20 0.37
GRM5 P41594 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
PIK3CA P42336 6/20 0.34
QPCT Q16769 1/20 0.33
QPCTL Q9NXS2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279161 1.00 SYK (0.39) SYKKAT2BBAZ2BNTRK1PDE4D
SCHEMBL274398 0.91 PDE4D (0.36) PDE4DPDE4APDE4BPDE4C
SCHEMBL279473 0.91 PDE4D (0.36) PDE4DPDE4APDE4BPDE4C
SCHEMBL279471 0.90 PTGDR2 (0.36) PDE4DPDE4APDE4BPDE4C
SCHEMBL274953 0.90 PTGDR2 (0.36) PDE4DPDE4APDE4BPDE4C
SCHEMBL278963 0.88 FPR2 (0.34)
SCHEMBL275957 0.88 FPR2 (0.34)
SCHEMBL278977 0.87 SYK (0.36) SYKKAT2BBAZ2BPDE4DPDE4A
SCHEMBL276886 0.87 SYK (0.36) SYKKAT2BBAZ2BPDE4DPDE4A
SCHEMBL275247 0.87 CHEK1 (0.38) SYKKAT2BBAZ2BPDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT SYK 2511/4885KAT2B 1420/4885BAZ2B 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.